Amgen Inc. $AMGN Shares Sold by Matrix Asset Advisors Inc. NY

Matrix Asset Advisors Inc. NY decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 103,549 shares of the medical research company’s stock after selling 2,682 shares during the quarter. Amgen comprises approximately 3.0% of Matrix Asset Advisors Inc. NY’s portfolio, making the stock its 11th biggest holding. Matrix Asset Advisors Inc. NY’s holdings in Amgen were worth $33,892,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Sequoia Financial Advisors LLC grew its position in Amgen by 2.3% during the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after buying an additional 3,619 shares during the period. Davis Capital Management acquired a new stake in shares of Amgen during the 3rd quarter valued at approximately $1,841,000. D.A. Davidson & CO. boosted its stake in shares of Amgen by 2.6% during the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock worth $68,590,000 after acquiring an additional 6,222 shares in the last quarter. Global Wealth Management Investment Advisory Inc. boosted its stake in shares of Amgen by 56.2% during the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock worth $3,684,000 after acquiring an additional 4,699 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its holdings in shares of Amgen by 18.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock worth $10,888,000 after acquiring an additional 6,115 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analyst/sector endorsements: recent analyst commentary (Zacks) highlights Amgen’s strong drug portfolio and resilience versus sector headwinds, which supports investor sentiment and helps the stock. The Zacks Analyst Blog Roche Holding, AT&T and Amgen
• Positive Sentiment: Inclusion in buy lists: Amgen appears in a recent “5 Best Pharma Stocks to Invest In Now” roundup, which can attract longer‑term inflows and positive sentiment from retail/institutional investors. 5 Best Pharma Stocks to Invest In Now
• Neutral Sentiment: Brokerage consensus: a recent survey shows AMGN carries an average “Hold” rating from brokerages — not a downgrade but a sign analysts see limited near‑term upside absent new catalysts. Amgen Inc. (NASDAQ:AMGN) Given Average Rating of “Hold” by Brokerages
• Negative Sentiment: Safety alert on Tavneos: the U.S. FDA has flagged multiple cases of drug‑induced liver injury — including deaths — linked to Amgen’s rare‑disease drug Tavneos (76 cases identified). The agency is urging closer monitoring and prompt discontinuation if liver damage is suspected; this poses regulatory, reputational and potential liability risks that could pressure the stock. US FDA warns of liver injury cases tied to Amgen’s rare disease drug FDA Says Amgen’s Tavneos Linked to Liver Injuries, Deaths
• Negative Sentiment: Biosimilars competition: Teva won FDA approval for a Prolia biosimilar (Ponlimsi) and advanced other biosimilar filings — increased biosimilars activity raises competitive pressure in areas where Amgen has legacy biologics, potentially weighing on future sales. TEVA’s Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $353.28 on Thursday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The business’s fifty day moving average price is $363.57 and its two-hundred day moving average price is $331.74. The stock has a market cap of $190.44 billion, a PE ratio of 24.83, a price-to-earnings-growth ratio of 3.49 and a beta of 0.47. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is 70.84%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on AMGN shares. Truist Financial raised their price objective on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. Oppenheimer set a $400.00 target price on Amgen and gave the company an “outperform” rating in a report on Thursday, January 29th. Jefferies Financial Group started coverage on Amgen in a research report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price target for the company. Argus lifted their price target on Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Finally, Citigroup boosted their price objective on shares of Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $354.60.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.